Search company, investor...



Grant | Alive

Total Raised


Last Raised

$50K | 5 yrs ago

About Infrascan

InfraScan is developing handheld screening devices for patients in two areas: stroke and traumatic brain injury. The company's flagship product, the Infrascanner handheld imaging device, uses near infrared (NIR) light to screen for intracranial bleeding in patients with head trauma. The results of screening can be used to expedite high-risk patients for CT scanning or surgical intervention.

Headquarters Location

3508 Market Street 4801 S Broad St, Suite 200

Philadelphia, Pennsylvania, 19014,

United States


Infrascan's Product Videos

Compete with Infrascan?

Ensure that your company and products are accurately represented on our platform.

Infrascan's Products & Differentiators

    Infrascanner Model 2000

    The Infrascanner is a handheld brain hematoma detector that caters to this unmet need. The Infrascanner™ provides an affordable, highly accurate, clinically effective system to detect and monitor Brain Hematomas, in patients with head trauma in settings where effective monitoring and triaging is necessary, and in places where access to CT Scans is restricted.

Expert Collections containing Infrascan

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Infrascan is included in 2 Expert Collections, including Medical Devices.


Medical Devices

11,917 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Infrascan Patents

Infrascan has filed 3 patents.

The 3 most popular patent topics include:

  • Fiber optics
  • Honeycombs (geometry)
  • Medical signs
patents chart

Application Date

Grant Date


Related Topics




Neuroimaging, Neuroscience, Honeycombs (geometry), Minicomputers, Physical oceanography


Application Date


Grant Date



Related Topics

Neuroimaging, Neuroscience, Honeycombs (geometry), Minicomputers, Physical oceanography



Latest Infrascan News

15:15 EDT Global Concussion Market to 2028 - Featuring Abbott, BrainScope and InfraScan Among Others

Mar 22, 2022

News provided by Share this article Share this article The concussion market is expected to growth from US$ 7,211.89 million in 2021 to US$ 9,272.03 million by 2028. It is estimated to grow at a CAGR of 3.7% during 2021-2028. According to the Centers for Disease Control and Prevention (CDC) a concussion is a type of traumatic brain injury-or TBI caused by a bump, blow, or jolt to the head or by a hit to the body causing the head and brain to move rapidly back and forth. The American Association of Neurological Surgeons report states that concussion symptoms can affect people in a variety of ways including vision, balance, and even mood. The World Health Organization (WHO) report states that approximately 1.3 million people die annually due to head injuries in road crashes. Road traffic collisions are prevalent in low-middle income countries (LMICs). Currently, the highest incidence of concussion cases is reported in North America and Europe. The Journal of Neurosurgery states that almost 64-74 million individuals may suffer from concussion cases every year with the highest cases witnessed in Southeast Asian and Western Pacific regions. According to the Brain Injury Research Institute's report, nearly 1.6 - 3.8 million athletes suffer from concussions annually. A study by the American Academy of Pediatrics states that sports-related concussion cases are highest among high school athletes and on the rise among younger athletes. For instance, 10% of all contact sports athletes sustain concussions yearly. Also, an athlete who sustains concussions is four to six times more prone to experience a second concussion. Further, the Centers for Disease Control and Prevention (CDC) report states that an estimated 273,272 children aged 17 years or younger were treated in United States emergency departments (EDs) intended for nonfatal traumatic injuries (TBIs) related to sports and recreation in 2016. Furthermore, the Centers for Disease Control and Prevention (CDC) report states that about 800,000 children are treated with concussion-related cases at EDs in the US. Also, in 2018, there were almost 223,050 TBI or concussion-related hospitalizations and 60,611 deaths in 2019. This represents more than 610 TBI-related hospitalizations and 166-TBI or concussion-related deaths per day. Population aging 75 years and older experience the highest numbers of TBI or concussion-related hospitalizations and deaths accounting for 32% of TBI or concussion hospitalization representing to 28% TBI or concussion associated deaths. The American Psychological Association (APA) sanctioned protocols particularly for computer-based testing and interpretation for distinguishing promising advantages in a clinical setting. The primary advantage of computer-based testing for concussion involves greater access by the clinicians, compatibility with conventional testing forms, and cost-effectiveness. Progressive software programs such as CogSport, concussion resolution index (CRI), and immediate post-concussion assessment and cognitive testing (ImPact) offer valid and all-inclusive testing instruments for assessing cognitive symptoms associated with sports-related concussions. The report of Frontiers S.A. states that concussion is a form of mild traumatic brain injury affecting thousands of Canadian children and adolescents annually. Timely access to primary and specialized care following the injury remains a challenge, especially in rural and remote communities. To overcome such challenging situations, telemedicine has emerged as an important tool for addressing disparities in healthcare accessibility for patients living in medically underserviced regions. This can be achieved with the proper establishment of novel telemedicine sites within established telemedicine networks; however, it can result in significant upfront capital costs for equipment, credentialing, and ongoing technical support and maintenance. Reasons to Buy Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the concussion market. Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in the concussion market, thereby allowing players across the value chain to develop effective long-term strategies. Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it. Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Key Topics Covered:

Infrascan Frequently Asked Questions (FAQ)

  • Where is Infrascan's headquarters?

    Infrascan's headquarters is located at 3508 Market Street, Philadelphia.

  • What is Infrascan's latest funding round?

    Infrascan's latest funding round is Grant.

  • How much did Infrascan raise?

    Infrascan raised a total of $50K.

  • Who are the investors of Infrascan?

    Investors of Infrascan include Philadelphia Pediatric Medical Device Consortium, Wharton Venture Initiation Program and BioAdvance.

  • Who are Infrascan's competitors?

    Competitors of Infrascan include Optovue, Tepha, Gammex, TNI medical, BrainScope, Median Technologies, HyperMed Imaging, Paragon Medical, Third Eye Diagnostics, MEC Dynamics and 13 more.

  • What products does Infrascan offer?

    Infrascan's products include Infrascanner Model 2000.

Compare Infrascan to Competitors

HyperMed Imaging Logo
HyperMed Imaging

HyperMed Imaging has been developing a new medical imaging device (OxyVu) which can differentiate between healthy and diseased tissue, improving both diagnosis and therapy for patients with diabetic foot ulcers and peripheral arterial disease. The Company received FDA clearance for the OxyVu product in November, 2006.

Third Eye Diagnostics

Third Eye Diagnostics is developing the Cerepress, a first-of-its-kind non-invasive intracranial pressure monitor that gathers information from the patient's eye. The technology is based on one issued patent, one pending patent, and two applications in progress on methods and apparatus that correlate ICP with measurements taken from the blood vessels within the eye. The Cerepress measures blood pressure in the eye's central retinal vein (CRV) which highly correlates to intracranial pressure.


Cervimark is a medical diagnostics company that is developing a screening test for the prediction of pregnancies at high risk for preterm delivery. The test is based on quantifying biomarkers found in secretions of pregnant patients and correlating the resulting data to risk of pre-term labor. Proof of concept for this test has been demonstrated in a small human trial.


ActiViews is engaged in developing multidisciplinary medical device. It develops a guiding system for interventional radiology procedures, initially for biopsy diagnosis. Activiews' system combines a sensor and a software package to enable simple, safe and accurate procedure. ActiViews' products aim to improve current procedures performed under CT (and other modalities in the future) through improvement of patient safety, reducing total time for procedure and potentially improving accuracy. At a later stage, the system will be integrated in imaging modalities to perform highly-focused radiation of carcinogenic tumors.


EyeSense develops an ophthalmic diagnostics system which can measure glucose levels without sampling blood. It is based on measuring the glucose in the interstitial fluid below the conjunctiva of the eye using a hand-held optical read-out device.

Cardiodynamics International Corporation

CardioDynamics was incorporated in 1993 and is committed to fundamentally changing drug management with ICG. The Company's primary product, the BioZ, uses proprietary Impedance Cardiography (ICG) technology to noninvasively assess a patient's hemodynamics, data which typically has been unavailable in the physician's office and available on a limited basis in the hospital only through a time-consuming, costly, and potentially dangerous invasive procedure called Pulmonary Artery Catheterization (PAC), or the Swan Ganz Catheter. Since the BioZ's ICG monitoring is noninvasive, it can be performed in outpatient areas such as physician offices, which have never before had access to hemodynamic information in treating heart failure, high blood pressure, pacemaker, and dialysis patients. In physician offices, BioZ monitoring can decrease long term costs of hypertension management through the use of appropriate drug therapies. The reduction of blood pressure results in a decrease of more costly cardiovascular conditions including heart failure, strokes, and heart attacks. In hospitals, BioZ monitoring on surgical or intensive care patients can decrease costs through the elimination of procedure risk, reduction of hospital stay, and minimization of hospital expenditures and personnel. BioZ monitoring can also provide valuable hemodynamic information in hospital areas where previously it has not been available, such as emergency departments, critical care, step-down units, and dialysis. In this new era of cost containment, healthcare payors and providers are demanding greater efficiency and cost-effectiveness without diminishing the quality of care. The BioZ's ICG monitoring systems provide a solution to meet this growing demand.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.